
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is poised for long-term success due to its innovative products, strong brand recognition, and expanding international presence, but recent challenges in retaining and utilizing customers within the Type 2 diabetes population have led to a cautious outlook. While the company is taking steps to address these issues, it may take some time before the effects are seen in financials. However, strong growth potential and a relatively attractive valuation make Insulet an interesting prospect for investors looking for a long-term investment in the healthcare industry.
Bears say
Insulet is facing many challenges that could potentially impact the company's profitability and growth. These challenges include cybersecurity threats, increased competition in the insulin pump market, supply chain and manufacturing risks, potential disruptions from GLP-1 RA and multi-agonist therapies, and regulatory and reimbursement shifts. The company also faces risks from intellectual property and patent litigation. Additionally, while Insulet has a strong new user adoption rate, the company's declining drug delivery revenue and uncertainty around its 2027 outlook could limit further growth potential in the near future. Overall, these factors contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares